DUBLIN–(BUSINESS WIRE)–The “Varicella
Zoster (HHV-3) Infections – Pipeline Insight, 2019” drug
pipelines has been added to ResearchAndMarkets.com’s
offering.
The report offers comprehensive Insight of the pipeline (under
development) therapeutics scenario and growth prospects across Varicella
Zoster (HHV-3) Infections development. The report provides detailed
coverage of the pipeline landscape for this mechanism of action,
equipped with data from multiple sources with complete pipeline analysis
by developmental stage, associated indications, route of administration
and molecule type.
Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.
The report assesses the active Varicella Zoster (HHV-3) Infections
pipeline products by developmental stage, product type, molecule type,
and administration route.
Scope of the report
-
The report provides a snapshot of the pipeline development for the
Varicella Zoster (HHV-3) Infections -
The report covers pipeline activity across the complete product
development cycle i.e. clinical, pre-clinical and discovery stages for
the Varicella Zoster (HHV-3) Infections -
The report provides pipeline product profiles which includes product
description, developmental activities, licensors & collaborators and
chemical information -
Provides pipeline assessment by monotherapy and combination therapy
products, stage of development, route of administration, and molecule
type for Varicella Zoster (HHV-3) Infections -
The report also covers the dormant and discontinued pipeline projects
related to the Varicella Zoster (HHV-3) Infections
Key Topics Covered:
1. Report Introduction
2. Varicella Zoster (HHV-3) Infections Overview
3. Pipeline Therapeutics
-
An Overview of Pipeline Products for Varicella Zoster (HHV-3)
Infections
4. Comparative Analysis
5. Products in Clinical Stage
- Product Description
- Research and Development
- Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
- Product Description
- Research and Development
- Product Development Activities
Companies Mentioned
- Astellas Pharma Inc.
- Beijing Minhai Biotechnology Co.
- Beijing Tiantan Biological Products Co.
- ContraVir Pharmaceuticals
- Epiphany Biosciences
- Foamix Pharmaceuticals Ltd.
- GeneOne Life Science
- GlaxoSmithKline Plc
- Green Cross Corporation
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/s3puhw
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Infectious
Diseases Drugs